Vertex reports mixed data on non-opioid drug, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but did not show a difference in reducing pain scores versus a placebo, sending its shares down nearly 14% premarket.
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals reported early Thursday that its non-opioid drug met the main goal in reducing back pain in a mid-stage study. But Vertex stock plunged as a placebo showed a similar reduction.Please watch the video at Investors.
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR). Suzetrigine, an oral, highly selective NaV1.8 pain signal ...
Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial
Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that causes back and leg pain.
Vertex’s Opioid Alternative Meets Goal in Back Pain Trial
Vertex Pharmaceuticals Inc.’s non-addictive drug helped patients with lower back pain, moving the company closer to selling an alternative to opioids in another type of pain.
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The company plans to use its new funds to get to “proof of concept” for its medicines.
Vertex's non-opioid drug meets main goal in mid-stage nerve pain trial
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug helped reduce pain tied to a condition caused by a pinched nerve in the spine during a mid-stage study.
2 Unstoppable Stocks to Buy and Hold for the Next Decade
Progress on that front will have a massive impact on Apple's revenue and, especially, its margins and bottom line. Though the ...
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...
Zacks.com on MSN2d
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market Today
Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.
Vertex公布腰骶神经根病变疼痛二期研究结果喜忧参半
波士顿 - 市值1152.4亿美元的生物技术板块巨头Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)宣布,其用于治疗腰骶神经根病变 (LSR)疼痛的药物suzetrigine的二期研究达到了主要终点。研究显示疼痛强度有统计学意义的降低。然而,安慰剂组也显示出类似程度的降低,这引发了人们对该药物相对于安慰剂的有效性的质疑。根据 ...
Vertex Pharmaceuticals price target raised to $494 from $490 at Stifel
Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up ...
20 innovative breakthroughs that will transform your health
There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...
Stifel Nicolaus Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $490.00 to $494.00 in a report released on Monday,Benzinga ...